AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19332185 — intervention group
Group type: COMPARATOR
Intervention: Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
Number of subjects: 20000
Study 16758048 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stented group (45 patients)
Number of subjects: 85
Study 16758048 — intervention group
Group type: COMPARATOR
Intervention: Stented group (40 patients)
Number of subjects: 85
Study 16758048 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stented group
Number of subjects: 85
Study 16758048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 14998843 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes)
Number of subjects: 0
Study 14998843 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-based or low-dose cisplatin-based doublets
Number of subjects: 0
Study 14998843 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 0
Study 14998843 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based combinations
Number of subjects: 0
Study 14998843 — intervention group
Group type: EXPERIMENTAL
Intervention: New biological agents
Number of subjects: 0
Study 14998843 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care improvements
Number of subjects: 0
Study 14998843 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic improvement
Number of subjects: 0
Study 12579942 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol aerosol
Number of subjects: 10
Study 12579942 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of salbutamol
Number of subjects: 10
Study 9006756 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus operation
Number of subjects: 50
Study 9006756 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise of thigh muscles
Number of subjects: 50
Study 9006756 — intervention group
Group type: COMPARATOR
Intervention: Bandaging
Number of subjects: 50
Study 9006756 — intervention group
Group type: COMPARATOR
Intervention: Repeat clinical examination
Number of subjects: 50
Study 9006756 — intervention group
Group type: COMPARATOR
Intervention: Overall surgery requirement
Number of subjects: 50
Study 9006756 — intervention group
Group type: COMPARATOR
Intervention: Symptoms related to patellofemoral joint or postoperative condition
Number of subjects: 50
Study 8314287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (4.05 g/die)
Number of subjects: 41
Study 8314287 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam (5.30 g/die)
Number of subjects: 41
Study 8314287 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam with furosemide (0.5 mg/kg body weight) intravenously
Number of subjects: 41
Study 8314287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime with furosemide (0.5 mg/kg body weight) intravenously
Number of subjects: 41
Study 3285835 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg torasemide
Number of subjects: 46
Study 3285835 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg torasemide
Number of subjects: 46
Study 3285835 — intervention group
Group type: EXPERIMENTAL
Intervention: furosemide (60 mg)
Number of subjects: 46
Study 3285835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 29141548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) program, conducted twice a week for six months.
Number of subjects: 140
Study 29141548 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 140
Study 28766500 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of memantine 10 mg
Number of subjects: 20
Study 28766500 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of memantine 10 mg
Number of subjects: 20
Study 26140004 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-sample lactose hydrogen breath test (4SLHBT)
Number of subjects: 120
Study 26140004 — intervention group
Group type: COMPARATOR
Intervention: Standard 13-sample lactose hydrogen breath test (LHBT)
Number of subjects: 120
Study 23267867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group (c-RFA with device removal and cleaning)
Number of subjects: 57
Study 23267867 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-with-cleaning group (c-RFA with device cleaning without removal)
Number of subjects: 57
Study 23267867 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-no-cleaning group (2 applications of c-RFA, device not removed or cleaned)
Number of subjects: 57
Study 23267867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group
Number of subjects: 57
Study 23267867 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-with-cleaning group
Number of subjects: 57
Study 23267867 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-no-cleaning group
Number of subjects: 57
Study 23267867 — intervention group
Group type: COMPARATOR
Intervention: Simple groups (both simple-with-cleaning and simple-no-cleaning)
Number of subjects: 57
Study 21727758 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based bench-stepping exercise training for 18 months
Number of subjects: 189
Study 19794994 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA (ropivacaine 0.2% + fentanyl 5 microg/mL at 4 mL/hr)
Number of subjects: 52
Study 19794994 — intervention group
Group type: COMPARATOR
Intervention: IV PCA (ketorolac 0.2 mg/kg + fentanyl 15 microg/mL at 1 mL/hr)
Number of subjects: 52
Study 16874871 — intervention group
Group type: EXPERIMENTAL
Intervention: B-OAzM (omeprazole 20 mg, bismuth subcitrate 240 mg, azithromycin 250 mg, and metronidazole 500 mg, all twice daily for 1-wk)
Number of subjects: 129
Study 16874871 — intervention group
Group type: COMPARATOR
Intervention: B-OAM (omeprazole 20 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and metronidazole 500 mg, all twice daily for 2-wk)
Number of subjects: 129
Study 12775734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg (intermittent)
Number of subjects: 24
Study 12775734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg (intermittent)
Number of subjects: 24
Study 12775734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg (continuous)
Number of subjects: 24
Study 12775734 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (carboplatin and paclitaxel)
Number of subjects: 24
Study 10835489 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 30 mg/day
Number of subjects: 54
Study 10835489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg/day
Number of subjects: 54
Study 10835489 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose beta-carotene
Number of subjects: 54
Study 10835489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg beta-carotene, 0 mg vitamin C)
Number of subjects: 54
Study 10835489 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 3 mg/day
Number of subjects: 54
Study 10835489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 50 mg/day
Number of subjects: 54
Study 9353803 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (twice-daily treatment sessions for 3 months)
Number of subjects: 54
Study 9353803 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily retention of the control probe)
Number of subjects: 54
Study 8384170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dFE: 30 mg per os)
Number of subjects: 7
Study 8384170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 7
Study 3885152 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment (mean serum level 5.1 mg/dL)
Number of subjects: 914
Study 3885152 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 914
Study 30043917 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-time noninvasive positive pressure ventilation (E-NPPV)
Number of subjects: 41
Study 30043917 — intervention group
Group type: COMPARATOR
Intervention: Short-time noninvasive positive pressure ventilation (S-NPPV)
Number of subjects: 41
Study 27212622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to nutritional recommendations for saturated fat and fiber consumption
Number of subjects: 2573
Study 27212622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to nutritional recommendations for added sugars
Number of subjects: 2573
Study 25543610 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective-loading group (loaded at week 6 with 150g force)
Number of subjects: 14
Study 25543610 — intervention group
Group type: COMPARATOR
Intervention: Delay-loading group (loaded at week 12 with 150g force)
Number of subjects: 14
Study 25543610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (loading and unloading mini-implants)
Number of subjects: 14
Study 23062766 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg/d MK-7 supplementation
Number of subjects: 60
Study 23062766 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 μg/d MK-7 supplementation
Number of subjects: 60
Study 23062766 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 23062766 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7 supplementation (both doses)
Number of subjects: 60
Study 20669650 — intervention group
Group type: EXPERIMENTAL
Intervention: FESS + SIT after operation
Number of subjects: 0
Study 20669650 — intervention group
Group type: COMPARATOR
Intervention: FESS only
Number of subjects: 0
Study 18562793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium patients
Number of subjects: 112
Study 18562793 — intervention group
Group type: COMPARATOR
Intervention: Control patients (matched for preoperatively assessed risk factors)
Number of subjects: 112
Study 16218396 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A)
Number of subjects: 0
Study 16218396 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12456604 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AMH levels
Number of subjects: 130
Study 12456604 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum AMH concentrations
Number of subjects: 130
Study 12456604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of inhibin B and FSH concentrations to AMH
Number of subjects: 130
Study 12456604 — intervention group
Group type: EXPERIMENTAL
Intervention: Post GnRH agonist rise in FSH and LH levels
Number of subjects: 130
Study 10479120 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine with MF59
Number of subjects: 0
Study 10479120 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine with alum
Number of subjects: 0
Study 10479120 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine with MF59 (fourth dose)
Number of subjects: 0
Study 10479120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8955652 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (TPT) administered as a 30-minute infusion daily for 5 days, with doses of 0.75 mg/m2, 1 mg/m2, and 0.75 mg/m2 in combination with cisplatin (CDDP) at doses of 50 mg/m2 and 75 mg/m2.
Number of subjects: 0
Study 8955652 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) administered either before TPT on day 1 or after TPT on day 5.
Number of subjects: 0
Study 1837251 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl baths
Number of subjects: 218
Study 1837251 — intervention group
Group type: COMPARATOR
Intervention: Underwater massage-showers
Number of subjects: 218
Study 6309730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg, single dose)
Number of subjects: 9
Study 6309730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (500 mg, single dose)
Number of subjects: 9
Study 31544476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (Group MM)
Number of subjects: 105
Study 31544476 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation meditation (Group PM)
Number of subjects: 105
Study 31544476 — intervention group
Group type: COMPARATOR
Intervention: Control meditation (Group CM)
Number of subjects: 105
Study 27939238 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Referral (ER)
Number of subjects: 0
Study 27939238 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief PA Counseling (BC)
Number of subjects: 0
Study 27070434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300-2700 mg daily)
Number of subjects: 47
Study 27070434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 25093663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Transversus Abdominis Plane (TAP) block (levobupivacaine = 150 mg)
Number of subjects: 65
Study 25093663 — intervention group
Group type: COMPARATOR
Intervention: Continuous Wound Infusion (CWI) (levobupivacaine = 150 mg first day and 12.5 mg/h thereafter)
Number of subjects: 65
Study 22928872 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (three weekly physical exercise sessions lasting 60-75 minutes each for 16 weeks)
Number of subjects: 150
Study 22928872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study 20071838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% infiltration (20 ml)
Number of subjects: 120
Study 20071838 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (Control Group)
Number of subjects: 120
Study 17884597 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 96
Study 17884597 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Trade-Off (TTO)
Number of subjects: 96
Study 16180047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique (LH) using polypropylene mesh
Number of subjects: 32
Study 16180047 — intervention group
Group type: COMPARATOR
Intervention: Bassini open conventional hernia repair (BH)
Number of subjects: 32
Study 12153805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier transform‐based spectral retinal imaging (SRI)
Number of subjects: 10
Study 12153805 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 10
Study 10492263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 220 microg bid
Number of subjects: 680
Study 10492263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 88 microg plus salmeterol (SL), 42 microg bid
Number of subjects: 680
Study 10492263 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TAA), 600 microg bid
Number of subjects: 680
Study 8584192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.005 mg/kg + Midazolam 0.2 mg/kg
Number of subjects: 40
Study 8584192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.005 mg/kg + Propofol 2.5 mg/kg
Number of subjects: 40
Study 8584192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg + Propofol 2.0 mg/kg
Number of subjects: 40
Study 8584192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-Propofol association
Number of subjects: 40
Study 1852093 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber
Number of subjects: 18
Study 1852093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6113127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (1 mg)
Number of subjects: 100
Study 6113127 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 100
Study 31977046 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI-based triple regimen given 4D a week
Number of subjects: 73
Study 31977046 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI-based triple regimen given 5D a week
Number of subjects: 73
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiograph (CXR) every 3 months for 2 years
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiograph (CXR) every 6 months for 2 years
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT every 3 months for 2 years
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT every 6 months for 2 years
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (primary outcome of the definitive trial)
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes on anxiety, satisfaction, and quality of life
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Local recurrence-free survival
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-free survival
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related complications
Number of subjects: 0
Study 31537562 — intervention group
Group type: EXPERIMENTAL
Intervention: Net healthcare costs related to surveillance
Number of subjects: 0
Study 27908546 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (Aminoleban EN)
Number of subjects: 51
Study 27908546 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 51
Study 25890211 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine (10 mg, 20 mg, 40 mg single doses; 10 mg multiple doses)
Number of subjects: 0
Study 23579010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillator (CRT-D)
Number of subjects: 1076
Study 23579010 — intervention group
Group type: COMPARATOR
Intervention: Implantable Cardioverter-Defibrillator (ICD)
Number of subjects: 1076
Study 22314633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) 5 g twice daily, n = 22
Number of subjects: 57
Study 22314633 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus CHM (Kun Bao Wan) 5 g twice daily plus sessions of acupuncture, n = 20
Number of subjects: 57
Study 22314633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy, n = 15
Number of subjects: 57
Study 19032447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (300 mg/day)
Number of subjects: 7
Study 19032447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium (20 mg/day)
Number of subjects: 7
Study 16434068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 20% sucrose
Number of subjects: 9
Study 16434068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 10% sucrose
Number of subjects: 9
Study 16434068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 5% sucrose
Number of subjects: 9
Study 16434068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry Kool Aid sweetened with 2.5% sucrose
Number of subjects: 9
Study 16434068 — intervention group
Group type: COMPARATOR
Intervention: Cherry Kool Aid unsweetened
Number of subjects: 9
Study 12604982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) 10^9 orally twice daily for 21 days in infants <1500 g
Number of subjects: 71
Study 12604982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) for 8 days in infants 1500 to 1999 g
Number of subjects: 71
Study 12604982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LGG treatment) for infants <1500 g
Number of subjects: 71
Study 12604982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LGG treatment) for infants 1500 to 1999 g
Number of subjects: 71
Study 10690513 — intervention group
Group type: EXPERIMENTAL
Intervention: HuM195 treatment
Number of subjects: 27
Study 10690513 — intervention group
Group type: EXPERIMENTAL
Intervention: HuM195 treatment after RA alone
Number of subjects: 27
Study 10690513 — intervention group
Group type: COMPARATOR
Intervention: RA alone (historical control)
Number of subjects: 27
Study 10690513 — intervention group
Group type: EXPERIMENTAL
Intervention: HuM195 treatment in newly diagnosed APL
Number of subjects: 27
Study 10690513 — intervention group
Group type: EXPERIMENTAL
Intervention: HuM195 treatment in second or third remission
Number of subjects: 27
Study 9327292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg daily)
Number of subjects: 0
Study 9327292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8402132 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem prophylaxis
Number of subjects: 411
Study 8402132 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole (control)
Number of subjects: 411
Study 2872055 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg
Number of subjects: 10
Study 30028484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein enteral diet providing 3 g ß‐glucan
Number of subjects: 40
Study 30028484 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet with 3 g maltodextrin
Number of subjects: 40
Study 26975233 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal adenomas only
Number of subjects: 2430
Study 26975233 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple proximal adenomas
Number of subjects: 2430
Study 24756009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg/day) plus metadoxine (500 mg three times daily)
Number of subjects: 70
Study 24756009 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg/day)
Number of subjects: 70
Study 22322966 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical α‐2 agonist brimonidine
Number of subjects: 60
Study 22322966 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 60
Study 22322966 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal‐directed intravenous administration of 5% albumin
Number of subjects: 60
Study 22322966 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal‐directed administration of lactated Ringer's solution
Number of subjects: 60
Study 20196184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (6-9 months)
Number of subjects: 39
Study 20196184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 39
Study 20196184 — intervention group
Group type: COMPARATOR
Intervention: Long-term lithium treatment
Number of subjects: 39